vs
Side-by-side financial comparison of STRATASYS LTD. (SSYS) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $137.0M, roughly 1.2× STRATASYS LTD.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -40.6%, a 111.8% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -2.2%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $2.5M).
Stratasys, Ltd. is an American-Israeli manufacturer of 3D printers, software, and materials for polymer additive manufacturing as well as 3D-printed parts on-demand. The company is incorporated in Israel. Engineers use Stratasys systems to model complex geometries in a wide range of polymer materials, including: ABS, polyphenylsulfone (PPSF), polycarbonate (PC), polyetherimide and Nylon 12.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
SSYS vs STOK — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $137.0M | $158.6M |
| Net Profit | $-55.6M | $112.9M |
| Gross Margin | 41.0% | — |
| Operating Margin | -16.6% | 70.2% |
| Net Margin | -40.6% | 71.2% |
| Revenue YoY | -2.2% | 3661.1% |
| Net Profit YoY | -109.0% | 528.0% |
| EPS (diluted) | — | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $137.0M | — | ||
| Q2 25 | $138.1M | — | ||
| Q1 25 | $136.0M | $158.6M | ||
| Q4 24 | — | $22.6M | ||
| Q3 24 | $140.0M | — | ||
| Q2 24 | $138.0M | — | ||
| Q1 24 | $144.1M | — | ||
| Q3 23 | $162.1M | — |
| Q3 25 | $-55.6M | — | ||
| Q2 25 | $-16.7M | — | ||
| Q1 25 | $-13.1M | $112.9M | ||
| Q4 24 | — | $-10.5M | ||
| Q3 24 | $-26.6M | — | ||
| Q2 24 | $-25.7M | — | ||
| Q1 24 | $-26.0M | — | ||
| Q3 23 | $-47.3M | — |
| Q3 25 | 41.0% | — | ||
| Q2 25 | 43.1% | — | ||
| Q1 25 | 44.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 44.8% | — | ||
| Q2 24 | 43.8% | — | ||
| Q1 24 | 44.4% | — | ||
| Q3 23 | 40.5% | — |
| Q3 25 | -16.6% | — | ||
| Q2 25 | -12.0% | — | ||
| Q1 25 | -9.1% | 70.2% | ||
| Q4 24 | — | -60.4% | ||
| Q3 24 | -18.2% | — | ||
| Q2 24 | -18.9% | — | ||
| Q1 24 | -17.0% | — | ||
| Q3 23 | -26.4% | — |
| Q3 25 | -40.6% | — | ||
| Q2 25 | -12.1% | — | ||
| Q1 25 | -9.6% | 71.2% | ||
| Q4 24 | — | -46.4% | ||
| Q3 24 | -19.0% | — | ||
| Q2 24 | -18.6% | — | ||
| Q1 24 | -18.0% | — | ||
| Q3 23 | -29.2% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $1.90 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | $-0.68 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $71.5M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $852.5M | $350.1M |
| Total Assets | $1.1B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $71.5M | — | ||
| Q2 25 | $71.1M | — | ||
| Q1 25 | $70.1M | $274.8M | ||
| Q4 24 | — | $128.0M | ||
| Q3 24 | $64.0M | — | ||
| Q2 24 | $70.9M | — | ||
| Q1 24 | $91.1M | — | ||
| Q3 23 | $104.6M | — |
| Q3 25 | $852.5M | — | ||
| Q2 25 | $902.4M | — | ||
| Q1 25 | $784.8M | $350.1M | ||
| Q4 24 | — | $229.0M | ||
| Q3 24 | $831.8M | — | ||
| Q2 24 | $850.5M | — | ||
| Q1 24 | $866.1M | — | ||
| Q3 23 | $883.1M | — |
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.0B | $406.9M | ||
| Q4 24 | — | $271.6M | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — | ||
| Q3 23 | $1.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.9M | $131.8M |
| Free Cash FlowOCF − Capex | $2.5M | $131.7M |
| FCF MarginFCF / Revenue | 1.8% | 83.0% |
| Capex IntensityCapex / Revenue | 3.2% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $-11.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $6.9M | — | ||
| Q2 25 | $-1.1M | — | ||
| Q1 25 | $4.5M | $131.8M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | $-4.5M | — | ||
| Q2 24 | $-2.4M | — | ||
| Q1 24 | $7.3M | — | ||
| Q3 23 | $-12.7M | — |
| Q3 25 | $2.5M | — | ||
| Q2 25 | $-8.4M | — | ||
| Q1 25 | $789.0K | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | $-6.3M | — | ||
| Q2 24 | $-4.9M | — | ||
| Q1 24 | $5.0M | — | ||
| Q3 23 | $-15.0M | — |
| Q3 25 | 1.8% | — | ||
| Q2 25 | -6.1% | — | ||
| Q1 25 | 0.6% | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q3 24 | -4.5% | — | ||
| Q2 24 | -3.6% | — | ||
| Q1 24 | 3.5% | — | ||
| Q3 23 | -9.3% | — |
| Q3 25 | 3.2% | — | ||
| Q2 25 | 5.3% | — | ||
| Q1 25 | 2.8% | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 1.6% | — | ||
| Q3 23 | 1.4% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
